Related Experiment Video
Updated: Jul 5, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Updates on pathogen inactivation of plasma using Theraflex methylene blue system
Jerard Seghatchian1, Wolfram H Walker, Stefan Reichenberg
1Blood Components Technology and Haemostasis/Thrombosis Consultancy, 50 Primrose Hill Road, London, UK. jseghatchian@btopenworld.com
Abstract:
Methylene blue (MB) treated plasma has been in clinical use for 15 years. The current Theraflex MB-Plasma system has a number of improved features compared with the original Springe methodology. This article gives an overview of processing methodology and recent developments, pathogen inactivation capacity, pharmacokinetics and toxicology, effects on plasma proteins and storage stability, clinical experience and future perspectives. Emphasises will be placed on most recent literature and updated information available.

